NCT04402788 2026-04-22
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
National Cancer Institute (NCI)
Phase 2/3 Recruiting
Clinical Trials
65 trialsNCT04981509 2026-04-21
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT06069726 2026-04-21
MOAB
Duke University
Phase 2 Recruiting
NCT06287775 2026-04-21
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT06646276 2026-04-21
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
Bristol-Myers Squibb
Phase 3 Recruiting
NCT03942328 2026-04-20
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
Mayo Clinic
Phase 1/2 Recruiting
NCT06066138 2026-04-20
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07226999 2026-04-20
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Pfizer
Phase 2/3 Recruiting
NCT07472517 2026-04-20
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy
Boehringer Ingelheim
Phase 3 Recruiting
NCT07538128 2026-04-20
Evaluating Safety, Tolerability, and Preliminary Efficacy of YSCH-01 Monotherapy and in Combination With Atezolizumab for Recurrent Glioblastoma
Huashan Hospital
Phase EARLY_PHASE1 Recruiting
NCT01810913 2026-04-17
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
Phase 2/3 Recruiting
NCT05019703 2026-04-17
Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS Study
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT04796012 2026-04-16
VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors
University of Texas Southwestern Medical Center
Phase 1/2 Recruiting
NCT05317858 2026-04-16
LIMITLESS
InSightec
Phase 3 Recruiting
NCT06496568 2026-04-16
A Study Evaluating Single-agent Inavolisib, Inavolisib Plus Atezolizumab, and Inavolisib Plus Pembrolizumab in PIK3CA-Mutated Cancers
Hoffmann-La Roche
Phase 1 Recruiting
NCT05581004 2026-04-15
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Recruiting
NCT06117891 2026-04-15
REFINE-IO
Bayer
Recruiting
NCT06161532 2026-04-14
Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as High Grade Neuroendocrine Carcinomas, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile C...
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07155174 2026-04-14
SEZanne
AbbVie
Phase 2 Recruiting
NCT07291076 2026-04-14
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT04802759 2026-04-13
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05333458 2026-04-13
Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT05862285 2026-04-13
UmbrellaMAX
Hoffmann-La Roche
Phase 3 Recruiting
NCT05968326 2026-04-13
IMCODE003
Genentech, Inc.
Phase 2 Recruiting
NCT07227597 2026-04-13
MK-6070-003
Merck Sharp & Dohme LLC
Phase 1/2 Recruiting
NCT07190833 2026-04-09
A Phase 1 Study of OTS-412 (Recombinant Oncolytic Vaccinia Virus) in Treatment-refractory Solid Tumor Patients (South Korea)
Bionoxx Inc.
Phase 1 Recruiting
NCT07235293 2026-04-09
A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer.
Kahr Medical
Phase 2 Recruiting
NCT07293468 2026-04-09
BIIRTH
Tuen Mun Hospital
Phase 2/3 Recruiting
NCT07339059 2026-04-09
Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Henry Ford Health System
Phase 2 Recruiting
NCT07407933 2026-04-09
A Study of YL201 in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 1/2 Recruiting
NCT04919382 2026-04-08
Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer
Big Ten Cancer Research Consortium
Phase 2 Recruiting
NCT07166406 2026-04-08
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial
NRG Oncology
Phase 3 Recruiting
NCT07195695 2026-04-08
Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
Boehringer Ingelheim
Phase 3 Recruiting
NCT06444815 2026-04-07
STEALTH-001
KaliVir Immunotherapeutics
Phase 1 Recruiting
NCT06632327 2026-04-07
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT05440708 2026-04-06
A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Tvardi Therapeutics, Incorporated
Phase 1/2 Recruiting
NCT04302025 2026-04-03
A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)
Genentech, Inc.
Phase 2 Recruiting
NCT06031441 2026-04-03
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Genentech, Inc.
Phase 1 Recruiting
NCT06096779 2026-04-03
Kirros
Genentech, Inc.
Phase 2 Recruiting
NCT06179069 2026-04-03
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer
Zai Lab (Hong Kong), Ltd.
Phase 1 Recruiting
NCT02693535 2026-04-02
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT05733598 2026-04-02
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
Replimune, Inc.
Phase 2 Recruiting
NCT04486352 2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT06807632 2026-04-01
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Recruiting
NCT04929223 2026-03-31
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
Phase 1 Recruiting
NCT06031233 2026-03-30
MINUTE
Isala
Phase 4 Recruiting
NCT04524871 2026-03-27
MORPHEUS-LIVER
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT07113691 2026-03-27
TIARA
Yale University
Phase 1 Recruiting
NCT07284121 2026-03-27
A Study to Evaluate Patient-Reported Satisfaction, Effectiveness, and Safety of Atezolizumab in Participants Treated in Routine Clinical Practice
Hoffmann-La Roche
Recruiting
NCT07059494 2026-03-23
Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant
Icahn School of Medicine at Mount Sinai
Phase 4 Recruiting